Pain in neuromyelitis optica—prevalence, pathogenesis and therapy
- 29 July 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Neurology
- Vol. 10 (9), 529-536
- https://doi.org/10.1038/nrneurol.2014.129
Abstract
Terrible, agonizing, wretched, sickening and unbearable--these are words frequently used by patients with neuromyelitis optica (NMO) to describe a very common symptom of their disease: pain. More than 80% of patients with NMO experience pain from this condition, which severely affects their quality of life. At present, there is no known therapy that produces satisfactory relief from NMO-associated pain. In fact, contemporary pain therapy is largely ineffective in these patients, suggesting that the mechanisms underlying pain in NMO differ substantially from those of other treatable causes of pain. Until now, the near-complete neglect of research into pain mechanisms in NMO has precluded rational pain therapy. In this Perspectives article, expertise from the fields of neuroimmunology, neurology and pain research is combined to explore, for the first time, the mechanisms underlying pain in patients with NMO, and to identify molecular and cellular targets for therapy.Keywords
This publication has 90 references indexed in Scilit:
- How to erase memory traces of pain and fearTrends in Neurosciences, 2013
- Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaActa Neuropathologica, 2013
- Association of Neuromyelitis Optica With Severe and Intractable PainArchives of Neurology, 2012
- Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabModern Rheumatology, 2012
- Morphine activates neuroinflammation in a manner parallel to endotoxinProceedings of the National Academy of Sciences of the United States of America, 2012
- Roles of glutamine in neurotransmissionNeuron Glia Biology, 2010
- Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelinationActa Neuropathologica, 2010
- Cellular and Molecular Mechanisms of PainCell, 2009
- Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis opticaAnnals of Neurology, 2009
- Pathological and protective roles of glia in chronic painNature Reviews Neuroscience, 2009